Skip to content
investormap

Oxford Science Enterprises

Venture capital

RollingLast verified 7 Nov 2026

Independent investment company and venture builder in partnership with the University of Oxford, providing patient capital to transform university research into high-impact science companies.

7 deals in the last 24 months, latest 6 Nov 2026. Derived from its deals in the news.

Key facts

Stages
Series A, Series C+
Sectors
Other deeptech, Biotech & pharma, Healthtech, Quantum, AI & machine learning
Typical round size
€142.6M (median of its recent deals, not a ticket)
Leads rounds
0% of recent deals with a known role
Eligible countries
United Kingdom
Provider based in
United Kingdom
Timing
Rolling applications
Focus
Oxford science spinouts; deep tech; life sciences; healthtech
How to apply
Application form · Apply on their site

Recent deals

Deals in the last 24 months
CompanyRoundSectorsAmountRoleAnnounced
Alethio Therapeutics · United KingdomSeries ABiotech & pharma€80.5Mparticipant6 Nov 2026
FluoRok · United KingdomSeries AMaterials & chemistry, Industrial & manufacturing, Cleantech€26.6Mparticipant5 Nov 2026
OMass TherapeuticsSeries C+Biotech & pharma€275.7Mparticipant15 Oct 2026
OQCSeries C+Quantum, Hardware & IoT€311.7M–3 Jun 2026
Oxford Quantum CircuitsSeries C+Quantum, Hardware & IoT€311.7M–3 Jun 2026
Quantum Motion · United KingdomSeries C+Quantum, Semiconductors€143.3Mparticipant7 May 2026
UltromicsSeries C+AI & machine learning, Healthtech, Medtech€49.3Mparticipant31 Jul 2025

Evidence

Short excerpts from the sources, in their original language, that back the facts above.

Status history

  • 6 Nov 2026: Rolling (first extraction)

Something wrong or out of date? Report an error.

Work at Oxford Science Enterprises? Claim this profile to confirm what you invest in.